Ironwood Pharmaceuticals - Class A (IRWD) closed at $4.39 on November 6, 2026, up 8.9% from the previous close, on volume of 3,798,066 shares (30-day average 1,759,607).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Calendar Call Sprd + OTM Call | 18-Dec-26 5 C : 19-Feb-27 5 C : 19-Feb-27 7.5 C | 3,000 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Ironwood Pharmaceuticals Non-GAAP EPS of $0.36 beats by $0.05, revenue of $133.04M beats by $11.47M
Seeking Alpha News (Thu, 5-Nov 7:14 AM ET)
Business Wire (Thu, 5-Nov 7:05 AM ET)
Ironwood Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 4-Nov 1:51 PM ET)
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
Business Wire (Wed, 28-Oct 4:05 PM ET)
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
Business Wire (Fri, 16-Oct 7:30 AM ET)
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Business Wire (Thu, 3-Sep 4:06 PM ET)
Market Chameleon (Mon, 5-Jan 5:36 AM ET)
Market Chameleon (Fri, 2-Jan 4:53 AM ET)
Market Chameleon (Fri, 2-Jan 2:59 AM ET)
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Ironwood Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol IRWD.
As of November 9, 2026, IRWD stock price climbed to $4.72 with 2,974,766 million shares trading.
IRWD has a beta of 0.45, meaning it tends to be less sensitive to market movements. IRWD has a correlation of 0.00 to the broad based SPY ETF.
IRWD has a market cap of $781.40 million. This is considered a Small Cap stock.
Last quarter Ironwood Pharmaceuticals - Class A reported $133 million in Revenue and $.36 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.05.
In the last 3 years, IRWD traded as high as $15.70 and as low as $.53.
The top ETF exchange traded funds that IRWD belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
IRWD has outperformed the market in the last year with a price return of +130.2% while the SPY ETF gained +13.4%. IRWD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +10.8% and +36.4%, respectively, while the SPY returned -1.8% and -1.0%, respectively.
IRWD support price is $4.25 and resistance is $4.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRWD shares will trade within this expected range on the day.
